Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tcm.2014.07.003 http://scihub22266oqcxt.onion/10.1016/j.tcm.2014.07.003 C4258878!4258878!25153017     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25153017&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25153017.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Trends+Cardiovasc+Med 2014 ; 24 (7): 285-95 Nephropedia Template TP {{tp|p=25153017|t=2014. An Update on Cardio-Oncology |pdf=|usr=}}{{25153017}} gab.com Text An Update on Cardio-Oncology JO: Trends Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=25153017 #FOAvip Over the past decades there have been great advancements in the survival outcome of patients with cancer. As a consequence, treatment regimens are being extended to patient populations, which would not have qualified in the past based on co-morbidities and age. Furthermore, the anti-cancer regimens, which have been and are being used, can cause considerable morbidity and even mortality. In fact, new drugs such as tyrosine kinase inhibitors have yielded unanticipated side effects in frequency and severity. The cardiovascular disease spectrum is an important element in all of these. In order to optimize the outcome of cancer patients with cardiovascular diseases existing prior to cancer treatment or developing as a consequence of it, a new discipline called ?cardio-oncology? has evolved over the past few years. Herein we review the latest developments in this field including cardiotoxicities, vascular toxicities, and arrhythmias. This field is taking on more shape as cardiologists, oncologists, and hematologists are forming alliances, programs, and clinics, supported by the development of expert consensus statements on best management approaches and care of the cancer patient with cardiovascular diseases. Twit Text FOAVip An Update on Cardio-Oncology ????Trends Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=25153017 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25153017 #FOAvip English Wikipedia <ref>{{Cite pmid|25153017}}</ref> An Update on Cardio-Oncology #MMPMID25153017 Herrmann J; Lerman A Trends Cardiovasc Med 2014[Oct]; 24 (7): 285-95 PMID25153017show ga Over the past decades there have been great advancements in the survival outcome of patients with cancer. As a consequence, treatment regimens are being extended to patient populations, which would not have qualified in the past based on co-morbidities and age. Furthermore, the anti-cancer regimens, which have been and are being used, can cause considerable morbidity and even mortality. In fact, new drugs such as tyrosine kinase inhibitors have yielded unanticipated side effects in frequency and severity. The cardiovascular disease spectrum is an important element in all of these. In order to optimize the outcome of cancer patients with cardiovascular diseases existing prior to cancer treatment or developing as a consequence of it, a new discipline called ?cardio-oncology? has evolved over the past few years. Herein we review the latest developments in this field including cardiotoxicities, vascular toxicities, and arrhythmias. This field is taking on more shape as cardiologists, oncologists, and hematologists are forming alliances, programs, and clinics, supported by the development of expert consensus statements on best management approaches and care of the cancer patient with cardiovascular diseases. äAn Update on Cardio-Oncology (epmc).pdf DeepDyve Pubget Overpricing